School of Medicine
Showing 251-260 of 546 Results
-
Hiroyuki Shimada
Professor of Pathology and, by courtesy, of Pediatrics
BioHiroyuki Shimada, MD, PhD, FRCPA (Hon), is Professor of Pathology and of Pediatrics at the Stanford University Medical Center. He was born in Tokyo, Japan, and completed MD (1973) and PhD (1982) at the Yokohama City University School of Medicine, Yokohama, Japan, and also completed his pathology training at the Children's Hospital (now the Nationwide Children’s Hospital) and the Ohio State University, Columbus, Ohio, USA (1988). Before moving to the Stanford University in 2019, he was Professor of Pathology (Clinical Scholar) at the University of Southern California Keck School of Medicine and working at the Children’s Hospital Los Angeles.
Dr. Shimada was Chair of the International Neuroblastoma Pathology Committee (1999-2017) and the founder of the International Neuroblastoma Pathology Classification (INPC). As Director of the COG (Children’s Oncology Group) Neuroblastoma Pathology Reference Laboratory (since 2001), he has been actively reviewing pathology samples of ~700 neuroblastoma cases per year from United States, Canada, Australia, and New Zealand. Pathology review results according to the INPC have been providing critical information for patient stratification and protocol assignment in the COG international neuroblastoma clinical trials. -
Andrew Young Shin
Clinical Professor, Pediatrics - Cardiology
Current Research and Scholarly InterestsSURF PROGRAM
The SURF program is an innovative collaboration between LPCH, Stanford University Hospital and the Stanford School of Engineering. The program has focused on improving quality and safety of patient care, improving hospital operations and promoting clinical effectiveness utilizing contemporary technologies such as machine learning, mathematical optimization, simulation and a variety of statistical, probabilistic and computational tools. The program has 2 independent funding mechanism to primarily improve patient care/hospital operations and improve academics for faculty within the department of Pediatrics at LPCH.
https://surf.stanford.edu/
CLINICAL EFFECTIVENESS
The Clinical Effectiveness (CE) Program is a funded program that aims to understand and improve unnecessary variation in healthcare delivery in order to optimize quality of care and reduce wasteful expenditures. The CE program has developed innovative programs such as Target Based Care, an award-winning intervention to reduce variation in hospital length of stay and currently a multi-center trial involving more than 20 hospitals in North America. In 2016, the CE program included the first CE fellowship program in a pediatric training program with 3 cycles of graduates. The CE program is supported by LPCH and a philanthropic gift by Susan Choe and Thomas Tobiason. -
Parveen Shiraz, MD
Instructor, Medicine - Blood & Marrow Transplantation
Current Research and Scholarly InterestsI am a physician-scientist in the Division of Blood and Marrow Transplantation-Cell Therapy (BMT-CT) at Stanford University. The focus of my laboratory research is the exploration of safe and more accessible forms of cell therapy for myeloid malignancies. We are studying multi-antigen targeting antibodies and engineered Natural Killer cells for myeloid malignancies.
-
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsTransplantation of defined populations of allogeneic hematopoietic cells. Specifically, the way in which hematopoietic cell grafts alter antigen specific immune responses to allo-, auto- and viral antigens. The cellular and molecular basis of resistance to engraftment of allogeneic hematopoietic stem cells.
-
Eugene Shkolyar, MD
Clinical Assistant Professor, Urology
BioEugene Shkolyar, MD is a urologic oncologist who specializes in treating patients with bladder, prostate, kidney, and testis cancers. He is a clinical assistant professor in the Department of Urology at the Stanford School of Medicine.
Dr. Shkolyar has expertise in open, endoscopic, and robotic surgery and in caring for patients with complex urologic oncology needs. Dr. Shkolyar is actively engaged in translational research, with a particular interest in integrating artificial intelligence into bladder cancer treatment and the development of novel biomarkers for cancer detection. His commitment to continual innovation ensures that his patients have access to the latest and most effective treatment options.
Dr. Shkolyar was born in Kyiv, Ukraine, and raised in New York. He attended Cornell University for his undergraduate education and went on to UCLA for medical school. Following medical school, Dr. Shkolyar completed a residency in urology at Stanford, where he developed his interest in urologic oncology, translational bladder cancer research and teaching. He went on to complete a two-year fellowship in urologic oncology at Stanford School of Medicine gaining additional skills in management of complex urologic cancers. Dr. Shkolyar is the recipient of numerous honors and awards, including membership in the Alpha Omega Alpha medical honors society and a research scholar award from the Urology Care Foundation. In addition, he has authored and co-authored numerous publications in urology, artificial intelligence, and device development.
Dr. Shkolyar is a member of the Society of Urologic Oncology, the American Society of Clinical Oncology, the American Urological Association, and the European Association of Urology.
